Aav vector-mediated liver gene therapy and its implementation for hemophilia

Abstract

Adeno-associated virus (AAV) vector is widely used in gene transfer purposes. Not only the experimental gene transfer but also applications toward disease therapy are promising. Numerous attempts are ongoing for this purpose. One of the most prominent examples is the sustained clinical benefi t in hemophilia gene therapy targeting the liver. These successes have been brought chiefl y by the progress in vectorology, especially capsid development. At present, one of the biggest issues is the presence of neutralizing antibody (NAb) against AAV vector capsid. Challenges have been made to conquer this problem. Although there are still some hurdles for wide clinical application, use of this vector will soon be a common practice for the treatment of suitable disease conditions.